NTRK3 and cancer: In addition, the IYIY-I2-BODIPY conjugate has demonstrated potential as a therapeutic agent for cancer treatment by selectively destroying the TrkC + tumor cells in mice upon PDT with high post-treatment survival rate26, and at the same time stimulating antitumor immunity in the host.